Hexarelin (also called Examorelin) is a synthetic growth hormone-releasing peptide that stimulates GH secretion and, uniquely among its class, also acts directly on the heart through a separate receptor pathway.
What it does
Hexarelin triggers growth hormone release by binding GHS-R1a, a receptor found on pituitary cells. When activated, GHS-R1a fires a signaling cascade — Gq protein → phospholipase C → calcium release → GH exocytosis — that pushes the pituitary to release GH in a pulse. Among all synthetic GH-releasing peptides (GHRPs), hexarelin produces the strongest GH response per microgram at this receptor, meaning it has the highest intrinsic activity of the class. The tradeoff is that it also elevates cortisol and prolactin more than selective options like ipamorelin, because those hormones share parts of the same downstream pathway Elizabeth 2025.
What sets hexarelin apart from every other GHRP is a second binding target: the CD36 scavenger receptor, found on cardiomyocytes (heart muscle cells). CD36 activation by hexarelin appears to reduce myocardial fibrosis (scarring of heart tissue), improve cardiac function following ischemia (oxygen deprivation), and slow atherosclerosis (plaque buildup in arteries). This cardioprotective effect operates independently of GH — it happens even in GH-deficient or hypophysectomized (pituitary-removed) animal models. No other GHRP shares this mechanism.
There is a practical ceiling to hexarelin's usefulness: GHS-R1a desensitizes faster with hexarelin than with any comparable peptide. Continuous use leads to tachyphylaxis — rapid tolerance — within weeks, meaning GH output drops even as dosing continues. This makes longer unbroken cycles essentially self-defeating.
What the evidence shows
Growth hormone stimulation Moderate human data for short-term GH release; limited long-term human data
Hexarelin reliably produces acute GH pulses in human subjects across multiple dosing studies, and per-dose potency is consistently higher than GHRP-2, GHRP-6, or ipamorelin in head-to-head comparisons. The clinical concern is rapid receptor desensitization: GH output in continuous-use protocols falls measurably within two to four weeks, which limits practical utility compared to peptides with slower tolerance curves Elizabeth 2025. Most published human work covers short-term administration windows rather than multi-month protocols.
Cardioprotection and cardiac function Strong mechanistic and rodent evidence; human trial data is sparse
Animal studies show hexarelin reduces infarct size, limits post-ischemic myocardial fibrosis, and preserves ejection fraction (the percentage of blood the heart pumps per beat) through CD36 receptor engagement — effects seen even in animals without functional pituitary glands, confirming this is GH-independent Elizabeth 2025. The CD36 pathway also shows anti-atherosclerotic activity in rodent models. Human trials in this area are limited; the cardiac indication remains compelling mechanistically but is not yet backed by robust clinical trial data.
Anti-aging and body composition Mostly extrapolated from GH physiology; limited direct human trial data
Like other GHRPs, hexarelin is used in self-reported protocols aimed at increasing lean mass, reducing fat, and improving recovery, effects attributed to downstream IGF-1 (insulin-like growth factor 1) elevation. Direct human trial evidence specifically for hexarelin in body composition is thin. Desensitization limits how much sustained GH exposure one can build with continuous use, which may blunt the body composition outcomes seen with more tolerable GHRPs in longer protocols Elizabeth 2025.
How it's used
In studies and self-reported protocols, doses range from 100 mcg subcutaneously once daily on the low end to 200–300 mcg once or twice daily at higher use levels. Half-life is approximately 55 minutes, so timing injections in the morning and before bed aligns with natural GH pulse patterns. Because of rapid receptor desensitization, most protocols keep continuous use to four to six weeks followed by an equivalent or longer off period. Hexarelin is administered subcutaneously (under the skin); no oral bioavailability data supports non-injectable use.
Side effects and safety
Hexarelin elevates cortisol and prolactin alongside GH — a less selective profile than ipamorelin and a relevant consideration for anyone with cortisol-sensitive conditions or diabetes, where elevated cortisol worsens insulin resistance. Common mild effects reported include increased appetite, water retention, and flushing. At moderate effect levels: headache, lethargy, and the cortisol/prolactin elevation noted above. The most clinically significant issue is tachyphylaxis — the receptor desensitizes faster than with any comparable GHRP, which is both a safety consideration (diminishing returns) and a practical limitation. As with all GH-stimulating agents, active malignancy is an absolute contraindication, since GH and IGF-1 can accelerate tumor growth. Pregnancy and Cushing syndrome (a state of chronic cortisol excess) are also absolute contraindications. Long-term safety data in humans is essentially absent; most of what is known comes from short study windows and self-reported use.
Bottom line
Hexarelin is the most potent GHRP at the GHS-R1a receptor and the only one with a direct cardiac mechanism via CD36, making it scientifically interesting for both GH secretion and heart-related applications. In practice, its fast receptor desensitization and less selective hormonal side-effect profile make it harder to use sustainably than alternatives like ipamorelin. The cardiac evidence is mechanistically strong but still needs human trial confirmation before it changes clinical practice.